• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BRCA1基因第1673位组氨酸缺失(p.His1673del)是一种与主要卵巢癌表型相关的致病突变。

BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.

作者信息

Zuntini Roberta, Cortesi Laura, Calistri Daniele, Pippucci Tommaso, Martelli Pier Luigi, Casadio Rita, Capizzi Elisa, Santini Donatella, Miccoli Sara, Medici Veronica, Danesi Rita, Marchi Isabella, Zampiga Valentina, Fiorentino Michelangelo, Ferrari Simona, Turchetti Daniela

机构信息

Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca sui Tumori Ereditari, UO Genetica Medica, Università di Bologna, Bologna, Italy.

Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.

出版信息

Oncotarget. 2017 Apr 4;8(14):22640-22648. doi: 10.18632/oncotarget.15151.

DOI:10.18632/oncotarget.15151
PMID:28186987
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5410251/
Abstract

We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer.The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor.The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.

摘要

我们研究了意大利艾米利亚 - 罗马涅地区14个家族中BRCA1基因变异p.His1673del的临床意义,其中包括20例乳腺癌和23例卵巢癌病例;4个家族表现为特定部位的卵巢癌。该变异在人类变异数据库中不存在,在BRCA1特定数据库中已被报道过3次;所有先证者在BRCA1基因座共享相同的罕见单倍型,这与共同祖先一致。采用Goldgar的多因素似然法来估计该变异为致病因素的概率,得出支持因果关系的比例为2,263,474:1。此外,计算机模拟表明,缺乏His1673的BRCA1蛋白可能与BARD1及其他相关蛋白的结合能力下降。所有6例卵巢癌以及4例乳腺癌中的2例显示BRCA1野生型等位基因缺失,在通过荧光原位杂交分析的4例卵巢癌中的3例中,这与包含该变异的17号染色体的重复有关。尽管多因素比例有力支持了该等位基因的致病性,但我们不能排除p.His1673del本身并无有害性,而是与同一祖先等位基因上另一个未检测到的突变相关联的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/024a386d58fe/oncotarget-08-22640-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/e472b747f1b6/oncotarget-08-22640-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/901712cca2bf/oncotarget-08-22640-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/024a386d58fe/oncotarget-08-22640-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/e472b747f1b6/oncotarget-08-22640-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/901712cca2bf/oncotarget-08-22640-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a753/5410251/024a386d58fe/oncotarget-08-22640-g003.jpg

相似文献

1
BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.BRCA1基因第1673位组氨酸缺失(p.His1673del)是一种与主要卵巢癌表型相关的致病突变。
Oncotarget. 2017 Apr 4;8(14):22640-22648. doi: 10.18632/oncotarget.15151.
2
Atypical cancer risk profile in carriers of Italian founder BRCA1 variant p.His1673del: Implications for classification and clinical management.意大利种系 BRCA1 突变 p.His1673del 携带者的非典型癌症风险特征:对分类和临床管理的影响。
Cancer Med. 2024 Aug;13(16):e70114. doi: 10.1002/cam4.70114.
3
Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.早发性乳腺癌和卵巢癌家族中肿瘤的种系BRCA1突变及野生型等位基因缺失
Clin Cancer Res. 1995 May;1(5):539-44.
4
Genetic analysis of a breast-ovarian cancer family, with 7 cases of colorectal cancer linked to BRCA1, fails to support a role for BRCA1 in colorectal tumorigenesis.对一个乳腺癌-卵巢癌家族进行的基因分析显示,有7例结直肠癌与BRCA1相关,但该分析未能证实BRCA1在结直肠癌发生过程中发挥作用。
Int J Cancer. 2000 Dec 1;88(5):778-82. doi: 10.1002/1097-0215(20001201)88:5<778::aid-ijc15>3.0.co;2-n.
5
BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.意大利南部(西西里岛)106个乳腺癌和卵巢癌家族的BRCA1基因检测:突变分析
Breast Cancer Res Treat. 2007 Nov;105(3):267-76. doi: 10.1007/s10549-006-9456-9. Epub 2007 Jan 13.
6
Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.特拉华州家族性胰腺癌的全州回顾性研究以及胰腺癌家族中基因突变的频率。
Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.
7
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.斯洛伐克遗传性乳腺癌/卵巢癌家系的综合遗传特征分析。
Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4.
8
G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.G1738R是希腊乳腺癌/卵巢癌患者中BRCA1的一个始祖突变:对其致病性的评估及其系谱历史推断
Breast Cancer Res Treat. 2008 Jul;110(2):377-85. doi: 10.1007/s10549-007-9729-y. Epub 2007 Sep 28.
9
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.BRCA1 和 BRCA2 家族乳腺癌、卵巢癌和对侧乳腺癌的外显率:老年时癌症发病率高。
Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.
10
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.在阿什肯纳兹族乳腺癌和卵巢癌家族中未发现基因组 BRCA1 和 BRCA2 重排。
Breast Cancer Res Treat. 2010 Sep;123(2):581-5. doi: 10.1007/s10549-010-0818-y. Epub 2010 Mar 11.

引用本文的文献

1
Clinical genetic services in the Emilia-Romagna region, Italy: current activity and open issues: a mixed-method study.意大利艾米利亚-罗马涅地区的临床遗传服务:当前活动与未决问题:一项混合方法研究
J Community Genet. 2025 Apr;16(2):139-150. doi: 10.1007/s12687-024-00750-7. Epub 2025 Jan 11.
2
Molecular analysis of BRCA1 and BRCA2 genes in La Rioja (Spain): five new variants.西班牙拉里奥哈地区BRCA1和BRCA2基因的分子分析:五个新变体
Hered Cancer Clin Pract. 2024 Oct 22;22(1):22. doi: 10.1186/s13053-024-00296-2.
3
Atypical cancer risk profile in carriers of Italian founder BRCA1 variant p.His1673del: Implications for classification and clinical management.

本文引用的文献

1
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.聚(ADP - 核糖)聚合酶抑制剂在高级别浆液性卵巢癌中的临床应用
Oncologist. 2016 May;21(5):586-93. doi: 10.1634/theoncologist.2015-0438. Epub 2016 Mar 28.
2
Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients.肾嗜酸细胞瘤:对11例患者中发生的42个肿瘤的临床病理及细胞遗传学研究
Pathology. 2016 Jan;48(1):41-6. doi: 10.1016/j.pathol.2015.11.009. Epub 2015 Dec 18.
3
Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites.
意大利种系 BRCA1 突变 p.His1673del 携带者的非典型癌症风险特征:对分类和临床管理的影响。
Cancer Med. 2024 Aug;13(16):e70114. doi: 10.1002/cam4.70114.
4
Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result in Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay.在用于基于商业下一代测序的同源重组缺陷检测的正在开发的拷贝数变异算法中,鉴定多重连接依赖探针扩增结果的假阳性
Ann Lab Med. 2024 Nov 1;44(6):617-620. doi: 10.3343/alm.2024.0051. Epub 2024 May 31.
5
The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic mutations.S型范可尼贫血的出现:双等位基因突变的表型谱。
Front Oncol. 2023 Dec 11;13:1278004. doi: 10.3389/fonc.2023.1278004. eCollection 2023.
6
Comprehensive clinical characterization of patients with : c.5017_5019del germline variant.携带c.5017_5019del种系变体患者的综合临床特征
Ann Surg Treat Res. 2022 Dec;103(6):323-330. doi: 10.4174/astr.2022.103.6.323. Epub 2022 Dec 8.
7
Identification of Eleven Novel Mutations in Tunisia: Impact on the Clinical Management of Related Cancers.突尼斯发现11种新突变:对相关癌症临床管理的影响
Front Oncol. 2021 Aug 20;11:674965. doi: 10.3389/fonc.2021.674965. eCollection 2021.
8
Analysis of BRCA1/2 variants of unknown significance in the prospective Korean Hereditary Breast Cancer study.在韩国遗传性乳腺癌前瞻性研究中分析意义未明的 BRCA1/2 变异体。
Sci Rep. 2021 Apr 19;11(1):8485. doi: 10.1038/s41598-021-87792-w.
9
Reclassification of and variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers.卵巢上皮性、输卵管和原发性腹膜癌中发现的 和 变异体的重新分类。
J Gynecol Oncol. 2020 Nov;31(6):e83. doi: 10.3802/jgo.2020.31.e83.
10
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.采用 ACMG/AMP 2015 指南重新解读遗传性乳腺癌/卵巢癌患者中意义未明的 BRCA1 和 BRCA2 变异。
Breast Cancer. 2019 Jul;26(4):510-519. doi: 10.1007/s12282-019-00951-w. Epub 2019 Feb 6.
BRCA1-BRCT/Abraxas复合物的结构揭示了DNA损伤位点处磷酸化依赖性的BRCT二聚化
Mol Cell. 2016 Feb 4;61(3):434-448. doi: 10.1016/j.molcel.2015.12.017. Epub 2016 Jan 14.
4
Identification of cis-suppression of human disease mutations by comparative genomics.通过比较基因组学鉴定人类疾病突变的顺式抑制
Nature. 2015 Aug 13;524(7564):225-9. doi: 10.1038/nature14497. Epub 2015 Jun 29.
5
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.BRCA1和BRCA2突变状态的精细组织病理学预测指标:来自BCAC、CIMBA和ENIGMA联盟的乳腺癌特征大规模分析
Breast Cancer Res. 2014 Dec 23;16(6):3419. doi: 10.1186/s13058-014-0474-y.
6
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.BRCA1和BRCA2基因突变的类型及位置与乳腺癌和卵巢癌风险的关联。
JAMA. 2015 Apr 7;313(13):1347-61. doi: 10.1001/jama.2014.5985.
7
Algorithmic approaches to protein-protein interaction site prediction.蛋白质-蛋白质相互作用位点预测的算法方法。
Algorithms Mol Biol. 2015 Feb 15;10:7. doi: 10.1186/s13015-015-0033-9. eCollection 2015.
8
Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.BRCA 检测中意义不明的变异:手术决策评估、风险感知和癌症困扰。
Clin Genet. 2013 Nov;84(5):464-72. doi: 10.1111/cge.12097. Epub 2013 Feb 20.
9
ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.ENIGMA--基于证据的种系突变等位基因解释网络:一项旨在评估 BRCA1 和 BRCA2 基因序列变异相关风险和临床意义的国际倡议。
Hum Mutat. 2012 Jan;33(1):2-7. doi: 10.1002/humu.21628. Epub 2011 Nov 3.
10
Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.比较 40 岁以下被诊断患有乳腺癌的澳大利亚女性中 BRCA1 和 BRCA2 致病性突变携带者与非携带者常见遗传变异和单倍型的频率。
BMC Cancer. 2010 Sep 1;10:466. doi: 10.1186/1471-2407-10-466.